Your Molecule
Your Molecule
Peptide Therapeutics
Peptide Therapeutics
Customized Formulation and Stability Solutions for Fragile Molecules
Early risk identification to design stable, patient-ready drug products
Stability and formulation excellence for parenteral applications.
Peptides are increasingly central to modern therapeutic pipelines, offering unique pharmacological profiles and high target specificity. However, their short half-life, structural fragility, and diverse physicochemical properties present considerable formulation challenges.
At Leukocare, we create tailored solutions that enhance peptide stability, usability, and manufacturability—helping you move confidently from discovery through clinical supply and commercialization.
Why peptides require special attention
Why peptides require special attention
Unlike large proteins or antibodies, peptides are inherently fragile and prone to multiple degradation pathways—including hydrolysis, oxidation, aggregation, and enzymatic breakdown. Their amphiphilic nature and conformational flexibility complicate formulation, often leading to solubility challenges, instability under physiological conditions, or short systemic half-life. Moreover, peptides often require high concentrations or special delivery systems (e.g., parenteral injections, depots, or sustained-release formulations) to achieve therapeutic effect.
Peptide drugs must be designed not only for biological efficacy but also for manufacturability, stability during storage, and usability for patients. This requires specialized excipients, optimized buffers, and in many cases lyophilization strategies. By integrating molecular knowledge with advanced DoE (Design of Experiments) and stability testing, we help to ensure peptide therapeutics are robust, scalable, and ready for regulatory scrutiny.
Explore our full modalities hub
Unlike large proteins or antibodies, peptides are inherently fragile and prone to multiple degradation pathways—including hydrolysis, oxidation, aggregation, and enzymatic breakdown. Their amphiphilic nature and conformational flexibility complicate formulation, often leading to solubility challenges, instability under physiological conditions, or short systemic half-life. Moreover, peptides often require high concentrations or special delivery systems (e.g., parenteral injections, depots, or sustained-release formulations) to achieve therapeutic effect.
Peptide drugs must be designed not only for biological efficacy but also for manufacturability, stability during storage, and usability for patients. This requires specialized excipients, optimized buffers, and in many cases lyophilization strategies. By integrating molecular knowledge with advanced DoE (Design of Experiments) and stability testing, we help to ensure peptide therapeutics are robust, scalable, and ready for regulatory scrutiny.
Explore our full modalities hub
Our expertise
Our expertise
We support a broad range of peptide therapeutics:
● Linear peptides (short chains, often highly susceptible to enzymatic degradation).
● Cyclic peptides (greater stability but requiring specific formulation strategies).
● Modified peptides (PEGylation, lipidation, or conjugated forms that require careful balance of hydrophilicity and lipophilicity).
Our expertise spans both liquid and lyophilized formulations, tailored to the intended route of administration and program requirements. We integrate advanced excipient systems, solubility enhancers, and stabilization strategies, while also ensuring compatibility with delivery devices and long-term storage. By combining empirical testing with predictive modeling, we de-risk
We support a broad range of peptide therapeutics:
● Linear peptides (short chains, often highly susceptible to enzymatic degradation).
● Cyclic peptides (greater stability but requiring specific formulation strategies).
● Modified peptides (PEGylation, lipidation, or conjugated forms that require careful balance of hydrophilicity and lipophilicity).
Our expertise spans both liquid and lyophilized formulations, tailored to the intended route of administration and program requirements. We integrate advanced excipient systems, solubility enhancers, and stabilization strategies, while also ensuring compatibility with delivery devices and long-term storage. By combining empirical testing with predictive modeling, we de-risk
Ready to talk about your bispecific formulation strategy?
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products
Key Focus Areas
-
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
Let’s Build the Right Formulation — Together
Partner with Leukocare for tailored, data‑driven solutions that bring your biologics closer to patients.
How we support you
1. Feasibility assessments to quickly identify risks and optimal formulation strategies by molecular modeling, benchmarking and forced degradation studies in the lab.
2. Excipient and buffer design informed by prior knowledge and data-driven pre-selection
3. Formulation and Lyophilization development for peptides requiring extended shelf life or improved robustness.
4. Comprehensive stability studies under ICH conditions, including accelerated and stress testing.